ATRA · Atara Biotherapeutics, Inc.
$9.40
-0.08 (-0.84%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our existing cash, cash equivalents and short-term investments as of June 30, 2026 will not be sufficient to fund our planned operations for at least the next twelve months from the date of issuance of these financial statements. These conditions raise substantial doubt about our ability to continue as a going concern for at least 12 months after the issuance of the accompanying condensed consolidated financial statements.”View the 10-Q filed Aug 12, 2026
Market Cap
$82.31M
Shares
10.04M
Volume · Oct 5
39.34K
Avg daily vol (3M)
57.9K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.48
Open$8.46
Day$8.25–9.68
52W close$4.18–18.09
Avg vol 30d47K
Short int404K · 4.0% float · 7.3d
Short vol51%
Last earningsNov 1, 2023
DataJan 2020–Oct 2026
Filing10-Q · Aug 12
Up next
filed Aug 12, 2026
call held Nov 1, 2023
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$6.19M
Trailing 12 months
Net income (TTM)
−$16.69M
Trailing 12 months
Revenue growth YoY
-96.4%
Year over year
Operating margin
-229.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$9.87M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+22.1%
Year over year · more shares
Price change (1Y)
-34.5%
Trailing year
Short interest
4.0%
Latest settlement · 7.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+14%
above
Price vs 50-day avg
+6%
above
RSI (14)
55
neutral
MACD trend
Negative
52-week position
38%
mid-range
Momentum
relative strength
1-month return
−1%
trailing
6-month return
+94%
trailing
YTD return
−48%
this year
Relative strength
+82%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
+9% holders QoQ · +4 funds added
Insider flow
Accumulating
Net +$959.1K over 90 days · 50% sells
Short interest
Falling
4.03% of float · ▼ -5.4% MoM · 7.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
37 holders — mid 3-yr range
Squeeze score
58
elevated · 0–100
Fundamentals
Revenue growth
−6%
Y/Y
EPS growth
+123%
Y/Y
Free cash flow
$-50.9M
Quant / Vol
risk profile
Volatility
144%
annualized · 1-yr
Max drawdown
−77%
past year
ATR
8.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+14%
Bullish
Price vs 50-day avg
+6%
Bullish
RSI (14)
55
Neutral
MACD trend
Negative
Bearish
52-week position
38%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $9 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
+9% holders QoQ · +4 funds added
Insider flow
Accumulating
Net +$959.1K over 90 days · 50% sells
Short interest
Falling
4.03% of float · ▼ -5.4% MoM · 7.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
37 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $4
Now $9 · 38%
Range high $18
vs 200-day avg +14%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ATRA
this stock
Atara Biotherapeutics, Inc.
|
$82.31M | -47.6% | -6.3% | — | 4.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ATRA | +7.6% | -0.5% | +93.9% | +11.5% | -47.6% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +7.8% | -0.1% | +81.7% | +10.6% | -60.5% |